Epidemiologic comparison of the first and second waves of coronavirus disease in Babol, North of Iran

Abstract

Background: A few studies compared the epidemiologic features of the first and second waves of coronavirus disease 2019 (COVID-19) outbreak. This research was carried out to compare the 1st and the 2nd waves of the epidemics in the northern Iran.

Methods: In this observational research, demographic, clinical and laboratory characteristics of the patients with COVID-19, admitted to four government hospitals affiliated to Babol University of Medical Sciences during the 1st and the 2nd waves of COVID-19 epidemics have been compared. The period from May 21, 2020 to September 21, 2020 was considered as the second wave of the epidemics while from February 19, 2020 to May 20, 2020, as the first wave of the outbreak in this region.

Results: Out of 6691 total hospitalized cases, 4374 (65.37%) including 1532 (49.6%) people in the first wave and 2842 (78.9%) in the second wave had RT-PCR test for disease confirmation. Among those who were examined with RT-PCR test, 2322 patients (53.1%) including 728 (31.4%) persons in the first wave and 1594 (68.6%) in the second wave were positive for SARS-CoV-2 RNA. 414 (56.9%) of the confirmed cases in the first wave and 767 (48.1%) in the second wave were males (p<0.001). Gastrointestinal symptoms were more incident in the second wave of the disease. However, severe respiratory conditions were more common during the first wave (p<0.001). Crude mortality rate was lower in the second wave of the outbreak (p<0.001).

Conclusion: Different epidemiologic characteristics were found in the second wave of COVID-19 outbreak in comparison with the first wave of the epidemics in northern Iran. 

Keywords: Coronavirus, Epidemiology, Disease outbreaks

Citation:
Jalali SF, Ghassemzadeh M, Mouodi S, et al. Epidemiologic comparison of the first and second waves of coronavirus disease epidemics in Babol, North of Iran. Caspian J Intern Med 2020; 11(Suppl 1): S544-550.
Iranian Ministry of Health, Treatment and Medical Education has reported a total of 504,281 people that were infected with the virus and 28,816 people died until October 13, 2020. In Babol, as an overgrown city located in the North of Iran, near the Caspian Sea, the first COVID-19 patient was reported on February 20, 2020. This city experienced two waves of the disease epidemic until October 2020.

A review of literatures describing the clinical signs and laboratory findings of 100 confirmed patients with COVID-19, aged 18 years and over admitted to the government hospitals of this city during the first wave of the disease showed that the average age of patients was 60.12 years; half of them were females; and 50% of patients had another comorbid disease, especially, diabetes mellitus, high blood pressure, coronary heart diseases, and chronic kidney disorders, respectively. In addition, the most incidental clinical manifestations of the patients were reported as anorexia, dry cough, dyspnea, fever and fatigue, respectively (4).

In this city, since May 21, 2020, coincided with the beginning of warm days of the year in this area, the number of confirmed cases of COVID-19 and referral rate to the governmental hospitals because this disease has increased again, and the second wave of the epidemic started. This research was carried out to describe the epidemiologic features of the disease in the second wave and to compare with the first wave of the COVID-19 outbreak. Of course, the comparison of different epidemiological dimensions of these two waves can be effective in the health policy-making and planning for the prevention and control of disease in the northern region of Iran (1, 5-7).

Methods

In this observational study, the demographic, clinical and laboratory characteristics of the patients admitted to the four government hospitals affiliated to Babol University of Medical Sciences, as suspected or confirmed cases with COVID-19, during the period from May 21, 2020 to September 21, 2020 (considered as the second wave of the epidemic in this region) have been compared with similar characteristics of the patients admitted in these hospitals from February 19, 2020 to May 20, 2020 (as the first wave of the epidemic). Collected data included the patient's age and gender, clinical symptoms, underlying disorders, need to ICU admission and tracheal intubation, and the final outcome of the disease at the time of hospital discharge. The source for data collection was the hospital-based data bank of the COVID-19 patients, named as Medical Care Monitoring Center (MCMC) which has been designed by the Ministry of Health, Treatment and Medical Education of Iran, and is used in the government hospitals of the country. The patients whose nasopharyngeal or oropharyngeal specimens were positive for SARS-CoV-2 RNA using real-time polymerase chain reaction (RT-PCR) have been considered as confirmed cases; and persons with defined clinical, epidemiologic and laboratory criteria, without confirmatory tests have been classified as suspected patients (8). Data analysis was performed using SPSS-18 software package. Chi-square and logistic regression tests were used for data analysis. A p-value less than 0.05 was considered as the significance level. This research has been approved by the Ethics Committee of Babol University of Medical Sciences, Iran with reference ID: IR.MUBABOL.HRI.REC.1399.119.

Results

Totally, 3091 confirmed and suspected patients were admitted in the four mentioned hospitals during the first wave of COVID-19 epidemic and 3600 individuals were admitted during the second wave. It shows that the crude number of patients admitted during the second wave of the disease was 1.41 (95% CI: 1.25-1.60) times more than the hospitalized people in the first wave. Mean age of patients in the first and second waves was 56.84±18.29 and 53.60±23.05 years, respectively (p<0.001). Out of 6691 total cases, 4374 (65.37%), including 1532 (49.6%) people in the first wave and 2842 (78.9%) in the second wave had RT-PCR test for disease confirmation.

Among those who were examined with RT-PCR test, 2322 (53.1%) patients including 728 (31.4%) persons in the first wave and 1594 (68.6%) in the second wave were positive for SARS-CoV-2 RNA. Crude number of hospitalized patients during the two waves of COVID-19 outbreak was divided as individuals with positive and negative RT-PCR test and those with no confirmatory test have been presented in figure 1.

Among the 2322 confirmed cases with COVID-19, 1181 (50.9%) individuals were males and 1141 (49.1%) were females; 414 (56.9%) of the confirmed cases in the first wave were males; however, this proportion for male gender was 767 (48.1%) in the second wave (p<0.001).
Age and sex distribution of confirmed cases has been presented in figure 2. One-hundred and twenty (7.5%) individuals of the confirmed cases in the second wave, and 75 (10.3%) in the first wave reported an obvious close contact with another well-known patient with coronavirus disease.

Clinical manifestations that were more common among patients with confirmed COVID-19 during the two waves of the disease has been summarized in Table 1. This table shows that fever (OR=1.98; 95% CI: 1.66-2.36; p<0.001), myalgia (OR=1.43; 95% CI: 1.17-1.76; P=0.001), and gastrointestinal (GI) symptoms such as diarrhea (OR=5.16; 95% CI: 2.07-12.83; p<0.001), taste disorders (OR=3.53; 95% CI: 1.06-11.81; P=0.029), nausea (OR=2.97; 95% CI: 1.62-5.45; p<0.001), vomiting (OR=2.56; 95% CI: 1.26-5.17; P=0.007) and abdominal pain (OR=2.36; 95% CI: 1.06-5.25; P=0.031) were more incident in the second wave of the disease compared to the first one. However, severe respiratory conditions and need to ICU care (p<0.001) or tracheal intubation (p<0.001) were observed with higher rate during the first wave of the disease. Underlying disorders comorbid to coronavirus disease among confirmed
cases have been presented in table 2. This table represents diabetes mellitus, cardiovascular disorders, high blood pressure, chronic renal disorders, malignancies, asthma and other respiratory disorders as the most common comorbidities in hospitalized patients with COVID-19, respectively. Also, during the second wave, cardiovascular disorders (P=0.033), hypertension (p<0.001), chronic renal disorders (P=0.044), malignancies (P=0.022), and opium use (P=0.046) were more prevalent among the study population, compared to the first wave. Totally, 127 (8.0%) of patients with confirmed COVID-19 during the 2nd wave, and 170 (23.4%) during the 1st wave expired. Crude mortality rate was lower in the second wave of the disease (p<0.001). During the second wave, the highest mortality rate was in the age group of 80-89 (n=32; 25.2%), 60-69 (n=30; 23.6%) and 50-59 (n=27; 21.3%) years, respectively; and during the first wave, the age-groups of 60-69 (n=41; 24.1%), 70-79 (n=41; 24.1%) and 50-59 (n=38; 22.4%) had the highest mortality rate. Distribution of the improved and expired patients during the two waves of the disease has been presented in figure 3.

Table 1. Distribution of clinical features in patients with confirmed COVID-19 during the two waves; North of Iran

| Clinical features                  | The 1st wave n=728 N(%) | The 2nd wave n=1594 N(%) | Total n=2322 N(%) | P-value | Crude Odds Ratio for the 2nd wave/the 1st wave (95% CI) |
|-----------------------------------|-------------------------|--------------------------|-------------------|---------|--------------------------------------------------------|
| Fever (measured or subjective)    | 330 (45.3)              | 990 (62.1)               | 1320 (56.8)       | <0.001  | 1.98 (1.66-2.36)                                        |
| Dry cough                         | 391 (53.7)              | 741 (46.5)               | 1132 (48.8)       | 0.001   | 0.75 (0.63-0.89)                                        |
| Respiratory distress              | 430 (59.1)              | 635 (39.8)               | 1065 (45.9)       | <0.001  | 0.46 (0.38-0.55)                                        |
| Myalgia                           | 161 (22.1)              | 461 (28.9)               | 622 (26.8)        | 0.001   | 1.43 (1.17-1.76)                                        |
| Nausea                            | 30 (4.2)                | 129 (8.3)                | 159 (6.8)         | <0.001  | 2.97 (1.62-5.45)                                        |
| Diarrhea                          | 5 (0.9)                 | 47 (2.9)                 | 52 (2.2)          | <0.001  | 5.16 (2.07-12.83)                                       |
| Vomiting                          | 9 (1.6)                 | 65 (4.1)                 | 74 (3.2)          | 0.007   | 2.56 (1.26-5.17)                                        |
| Impaired consciousness            | 26 (3.6)                | 43 (2.7)                 | 69 (3.0)          | 0.250   | 0.75 (0.46-1.23)                                        |
| Abdominal pain                    | 7 (1.3)                 | 47 (2.9)                 | 54 (2.3)          | 0.031   | 2.36 (1.06-5.25)                                        |
| Anorexia                          | 5 (0.7)                 | 29 (1.8)                 | 44 (2.1)          | 0.195   | 0.66 (0.35-1.24)                                        |
| Taste disorders                   | 3 (0.4)                 | 23 (1.4)                 | 26 (1.1)          | 0.029   | 3.53 (1.06-11.81)                                       |
| Olfactory disorders               | 3 (0.4)                 | 16 (1.0)                 | 19 (0.8)          | 0.143   | 2.45 (0.71-8.42)                                        |
| Convulsion                        | 3 (0.4)                 | 11 (0.7)                 | 14 (0.6)          | 0.423   | 1.68 (0.47-6.03)                                        |
| Need to ICU care                  | 129 (17.7)              | 140 (8.8)                | 269 (11.6)        | <0.001  | 0.45 (0.35-0.58)                                        |
| Need to tracheal intubation        | 168 (23.1)              | 57 (3.6)                 | 225 (9.7)         | <0.001  | 0.12 (0.09-0.17)                                        |

Table 2. Comorbid disorders in hospitalized patients with confirmed COVID-19, North of Iran

| Underlying disorders comorbid to coronavirus disease | The 1st wave n=728 N(%) | The 2nd wave n=1594 N(%) | Total n=2322 N(%) | P-value | Crude Odds Ratio for the 2nd wave/the 1st wave (95% CI) |
|-----------------------------------------------------|-------------------------|--------------------------|-------------------|---------|--------------------------------------------------------|
| Diabetes mellitus                                  | 154 (21.2)              | 363 (22.8)               | 517 (22.3)        | 0.384   | 1.10 (0.89-1.36)                                        |
| Cardiovascular disorders                           | 157 (21.6)              | 284 (17.8)               | 441 (19.0)        | 0.033   | 0.79 (0.63-0.98)                                        |
| Hypertension                                       | 46 (6.3)                | 275 (17.3)               | 321 (13.8)        | <0.001  | 3.09 (2.23-4.28)                                        |
| Chronic renal disorders                            | 26 (3.6)                | 88 (5.5)                 | 114 (4.9)         | 0.044   | 1.58 (1.01-2.47)                                        |
| Malignancies                                        | 8 (1.1)                 | 41 (2.6)                 | 49 (2.1)          | 0.022   | 2.38 (1.11-5.10)                                        |
| Asthma                                              | 20 (2.7)                | 27 (1.7)                 | 47 (2.0)          | 0.094   | 0.61 (0.34-1.10)                                        |
| Other respiratory disorders (Except Asthma)         | 16 (2.2)                | 22 (1.4)                 | 38 (1.6)          | 0.150   | 0.62 (0.33-1.19)                                        |
| Opium abuse                                         | 3 (0.4)                 | 21 (1.3)                 | 24 (1.0)          | 0.046   | 3.22 (0.96-10.84)                                       |
| Chronic neurologic disorders                       | 8 (1.1)                 | 20 (1.3)                 | 28 (1.2)          | 0.750   | 1.14 (0.50-2.61)                                        |
| Smoking                                             | 6 (0.8)                 | 12 (0.8)                 | 18 (0.8)          | 0.854   | 0.91 (0.34-2.44)                                        |
| Chronic hematopoietic disorders                    | 6 (0.8)                 | 9 (0.6)                  | 15 (0.6)          | 0.469   | 0.68 (0.24-1.93)                                        |
| Chronic liver diseases                             | 1 (0.1)                 | 7 (0.4)                  | 8 (0.3)           | 0.250   | 3.21 (0.39-26.11)                                       |
| Chronic immunologic disorders (Except HIV/AIDS)     | 3 (0.4)                 | 6 (0.4)                  | 9 (0.4)           | 0.898   | 0.91 (0.23-3.67)                                        |
| HIV/AIDS                                            | 2 (0.3)                 | 1 (0.1)                  | 3 (0.1)           | 0.187   | 0.23 (0.02-2.52)                                        |
| Other comorbid disorders                           | 76 (10.4)               | 138 (8.7)                | 214 (9.2)         | 0.168   | 0.81 (0.61-1.09)                                        |
Discussion

This research describes the two waves of COVID-19 epidemic in the northern region of Iran. Our results showed that the first wave of the disease, which occurred during the relatively cold months of the year, was associated with more deaths; however, the second wave of the disease, which began at the start of the relatively warm months of the year, although more patients were hospitalized during the wave, mortality rate dropped significantly. The first wave of the epidemic began when no standard and comprehensive protocol was published for treatment of patients, worldwide; and scientific evidence was mainly the results of experiences from limited studies, usually in small sample size populations or small study areas, that presented various treatment approaches to health-care professionals (9). In addition, at that time, widespread RT-PCR assays for precise diagnosis of COVID-19 in symptomatic patients were not easily available; in this way, fewer patients have been examined using RT-PCR test during the first wave of the disease. Babol University of Medical Sciences has established the first RT-PCR laboratory since March 5, 2020, and also improved the instruments and trained staff to perform this assay over time, therefore, case confirmation has increased in the second wave compared to the first one. Another factor that might have impact on final outcome of the patients during the two waves is the availability of different treatment facilities in the state hospitals of the region (10). During the first wave, more patients with COVID-19 required respiratory support (11, 12); furthermore, age, gender, disease severity and comorbidities are other important factors that can justify the observed difference in mortality rate during these two waves (13-15).

Mean age was lower in the second wave compared to the first one. A systematic review and meta-analysis reported a median age of 46.2 years among the patients with a confirmed COVID-19 diagnosis (16). Although the exact cause for the difference of the patients' age between the two waves is unknown, it has been hypothesized that older adults have a further risk of SARS-CoV-2 infection, disease-related hospitalization and more severe complications (4, 17, 18). This can be associated to identify older adults in the first wave of the outbreak and younger adults in the later phases of the epidemic.

In our study, women were affected with a higher proportion than men during the second wave of the disease, while during the first wave, men showed further vulnerability to the disease. It may be due to immunological, lifestyle behaviors such as smoking, health related self-care, or other factors that can potentially change the gendered impacts of the epidemic (19, 20). However, our current data on sex differences is incomplete. Gastrointestinal manifestations were more common in the second wave. Literature review shows that GI features can be present in more than 25% of patients with COVID-19 (21). The most incidental GI symptoms in these patients have been reported as diarrhea, nausea and/or vomiting and abdominal pain (21-24). It is important to be aware of gastrointestinal symptoms in both adult and pediatric populations. Be unfamiliar to these presentations can lead to delay in early diagnosis and treatment of patients with COVID-19, and cause serious complications.

Diabetes mellitus, cardiovascular disorders, hypertension, chronic renal disorders, malignancies, asthma and other respiratory disorders were the most common comorbidities in hospitalized patients with confirmed COVID-19; and all of these comorbidities were more prevalent in the second wave of the epidemic compared to the first wave. A recent meta-analysis revealed that medical comorbidities can lead to higher incidence of serious events such as ICU admission, pneumonia, acute respiratory distress syndrome, mechanical ventilation, and death in patients with COVID-19; for example, presence of chronic respiratory disorders, chronic
kidney diseases, cardiovascular diseases, and diabetes mellitus caused a 6.6, 5.3, 4.5, and 3.07 times higher risk of developing serious events in COVID-19 patients, respectively (25). The most important strength point of this study is its novelty on describing the two waves of COVID-19 outbreak. Up to this writing, the number of studies that described more than one wave of the COVID-19 outbreak was very limited (26). We did not report details of laboratory and imaging characteristics of the patients and this can be presented as a limitation of this research.

In conclusion, different epidemiologic characteristics were observed in the second wave of COVID-19 outbreak in comparison with the first wave of the epidemic in the northern region of Iran.

Acknowledgments
We hereby thank the cooperation of all health service providers in different departments affiliated to Babol University of Medical Sciences in managing the COVID-19 epidemic.

Funding: This study has been supported financially by Babol University of Medical Sciences, Iran.

Conflict of Interests: No conflict of interests has been observed.

References
1. Ali I. COVID-19: Are we ready for the second wave? Dis Med Public Health Prep 2020: 1-3. Available at: https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/article/covid19-are-we-ready-for-the-second-wave/F3D6F6D197A0CE124A3BBEACCF86651D
2. Abdi M. Coronavirus disease 2019 (COVID-19) outbreak in Iran: Actions and problems. Infect Control Hosp Epidemiol 2020; 41: 754-5.
3. Salimi R, Gomar R, Heshmati B. The COVID-19 outbreak in Iran. J Glob Health 2020; 10:010365.
4. Javanian M, Bayani M, Shokri M, et al. Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study. Rom J Intern Med 2020; 58: 161-7.
5. Strzelecki A. The second worldwide wave of interest in coronavirus since the COVID-19 outbreaks in South Korea, Italy and Iran: A Google Trends study. Brain Behav Immun 2020; 88: 950-51.
6. Baloch S, Baloch MA, Zheng T, Pei X. The Coronavirus Disease 2019 (COVID-19) Pandemic. Tohoku J Exp Med 2020; 250: 271-8.
7. Nicola M, O'Neill N, Sohrabi C, et al. Evidence based management guideline for the COVID-19 pandemic-Review article. Int J Surg 2020; 77: 206-16.
8. National Notifiable Diseases Surveillance System (NNDSS). Coronavirus Disease 2019 (COVID-19) 2020 Interim Case Definition. CDC 2020. Available at: https://www.google.com/search?q=oronavirus+Disease+2019+(COVID-19)+2020+Interim+Case+Definition.+2020.&aqs=chrome.69i57.762j0j15&sourceid=chrome&ie=UTF-8
9. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020; 370: m2980.
10. Asgharpour M, Mehidinezhad H, Bayani M, et al. Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19). BMC Nephrol 2020; 21: 356.
11. Seyfi S, Amri P, Mouodi S. New modalities for non-invasive positive pressure ventilation: A review article. Caspian J Intern Med 2019; 10: 1-6.
12. Guérin C, Lévy P. Easier access to mechanical ventilation worldwide: an urgent need for low income countries, especially in face of the growing COVID-19 crisis. Eur Respir J 2020; 55: 2001271.
13. Lu L, Zhong W, Bian Z, et al. A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis. J Infect 2020; 81: e18-e25.
14. Qiu P, Zhou Y, Wang F, et al. Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis. Aging Clin Exp Res 2020; 32: 1869-78.
15. Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates. Int J Infect Dis 2020; 101: 138-48.
16. Khalili M, Karamouzian M, Nasiri N. Epidemiological characteristics of COVID-19: a systematic review and meta-analysis. Epidemiol Infect 2020; 148: e130.
17. Shahid Z, Kalayanamitra R, McClafferty B, et al. COVID-19 and older adults: what we know. J Am Geriatr Soc 2020; 68: 926-9.
18. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY) 2020; 12: 9959-81.
19. Wenham C, Smith J, Morgan R; Gender and COVID-19 Working Group. COVID-19: the gendered impacts of the outbreak. Lancet 2020; 395: 846-8.
20. Rozenberg S, Vandromme J, Martin C. Are we equal in adversity? Does Covid-19 affect women and men differently? Maturitas 2020; 138: 62-8.
21. Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol 2020; 26: 2323-32.
22. Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology 2020; 158: 1518-9.
23. Mandal A, Konala VM, Adapa S, Naramala S, Gayam V. Gastrointestinal manifestations in COVID-19 infection and its practical applications. Cureus 2020; 12: e8750.
24. Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Transl Res 2020; 226: 57-69.
25. Nandy K, Salunke A, Pathak SK, et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr 2020; 14: 1017-25.
26. Cacciapaglia G, Cot C, Sannino F. Second wave COVID-19 pandemics in Europe: a temporal playbook. Sci Rep 2020; 10: 15514.